Nitrogen
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Nitrogen: From No Established Indication to 16q24.1 Microdeletion Syndrome
One-Sentence Summary
Nitrogen (DrugBank DB09152) has no recorded original indication and no documented mechanism of action in this evidence pack. TxGNN predicts a possible link to 16q24.1 microdeletion syndrome, but this is a model-score-only prediction, with 0 clinical trials and 0 publications currently supporting the association.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no recorded indication in evidence pack |
| Predicted New Indication | 16q24.1 microdeletion syndrome |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Nitrogen, and no original indication is recorded in this evidence pack. As elemental nitrogen has no well-characterized pharmacological target, there is no established biological pathway connecting it to 16q24.1 microdeletion syndrome — a rare chromosomal deletion disorder. The high TxGNN score is not corroborated by any independent clinical or mechanistic evidence and is best interpreted as a knowledge-graph connectivity artifact rather than a pharmacologically grounded hypothesis.
The same pattern holds across all four top-ranked predictions for this drug (16q24.1 microdeletion syndrome, primary childhood interstitial lung disease, isolated pulmonary capillaritis, congenital pulmonary lymphangiectasia) — all are rated L5 with a “Hold” recommendation, and only one (rank 2) has an associated clinical trial, which is a purely observational genetic/epidemiological study with no drug intervention. None of the four candidates currently offer a testable mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No marketing authorizations on record — Nitrogen (DB09152) is currently Not Marketed, with 0 licenses in the regulatory dataset.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA label warnings/contraindications are flagged as a Blocking data gap (DG001) — this information must be obtained before any safety evaluation (S1 stage) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: All predicted indications for this candidate are supported only by TxGNN model scores (L5), with no clinical trials or literature evidence establishing a drug-disease link, and critical safety data (mechanism of action, warnings, contraindications) remain unresolved data gaps — the evaluation cannot advance past S0/S1 in its current state.
To proceed, the following is needed:
- TFDA package insert warnings and contraindications (Blocking gap, DG001)
- Confirmed mechanism of action for Nitrogen (DG002)
- Confirmed original/approved indication(s) for Nitrogen
- Independent clinical or mechanistic evidence linking Nitrogen to any of the four predicted indications before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.